Andor Labs LLC

Andor Labs LLC was paid $11.15M by Medicaid between Jan 2018 and Dec 2024, across 119 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 23% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in North Carolina

Rank by total paid#16 of 128

Median peer was paid$268K

This provider vs. median42×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	7,795	$768K
2019	7,567	$801K
2020	25,440	$1.66M
2021	59,212	$2.87M
2022	45,120	$2.02M
2023	54,865	$2.27M
2024incomplete	23,542	$775K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	23%	17,020	10,386	$2.62M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	18%	33,575	16,532	$2.01M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	14%	29,140	21,286	$1.59M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	13%	16,143	10,938	$1.45M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	9.6%	9,263	5,723	$1.07M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	6.1%	12,643	8,788	$683K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	4.1%	25,013	12,579	$460K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	2.2%	14,740	8,913	$250K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	1.2%	4,395	3,087	$134K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	3,728	666	$89K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	2,797	2,260	$74K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	406	325	$49K

107 more codes

80061	Lipid panel	<1%	3,812	$46K
84443	Thyroid stimulating hormone (TSH)	<1%	3,012	$42K
80053	Comprehensive metabolic panel	<1%	3,785	$28K
81316		<1%	143	$28K
86328		<1%	1,591	$28K
83036	Hemoglobin; glycosylated (A1C)	<1%	2,717	$24K
82607		<1%	1,597	$22K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	3,193	$21K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	575	$19K
87653		<1%	804	$18K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	140	$16K
87640		<1%	754	$15K
82746		<1%	1,028	$14K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	613	$13K
87500		<1%	596	$13K
81240		<1%	201	$12K
87541		<1%	568	$12K
87486		<1%	568	$12K
87641		<1%	567	$11K
87581		<1%	565	$11K
84439		<1%	1,132	$9K
36415	Collection of venous blood by venipuncture	<1%	4,813	$9K
80050	General health panel	<1%	683	$8K
83992		<1%	435	$8K
80359		<1%	467	$7K
80373		<1%	465	$7K
80372		<1%	440	$7K
80368		<1%	454	$7K
80369		<1%	454	$7K
80354		<1%	453	$7K
80348		<1%	449	$7K
80346		<1%	444	$7K
80361		<1%	442	$7K
80324		<1%	441	$7K
80358		<1%	441	$7K
80353		<1%	441	$7K
80365		<1%	441	$7K
80355		<1%	436	$7K
80337		<1%	436	$7K
80363		<1%	408	$7K
80366		<1%	427	$7K
80333		<1%	423	$7K
83550		<1%	851	$7K
80338		<1%	422	$7K
80343		<1%	422	$7K
80345		<1%	421	$7K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	253	$6K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	249	$6K
86638		<1%	556	$6K
80356		<1%	344	$6K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	234	$5K
84153		<1%	295	$5K
82728		<1%	300	$4K
84481		<1%	230	$4K
85027		<1%	605	$4K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	137	$3K
84403		<1%	128	$3K
80321		<1%	192	$3K
80323		<1%	178	$3K
86803		<1%	199	$2K
87481		<1%	88	$2K
83540		<1%	320	$2K
84480		<1%	139	$2K
83090		<1%	99	$2K
82670		<1%	69	$2K
80048	Basic metabolic panel (calcium, ionized)	<1%	186	$1K
84436		<1%	298	$1K
82652		<1%	39	$1K
83735		<1%	216	$1K
86708		<1%	123	$1K
87340		<1%	164	$1K
84466		<1%	102	$1K
86705		<1%	123	$1K
83001		<1%	70	$1K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	17	$862.01
87631		<1%	13	$840.61
80076		<1%	106	$810.93
84479		<1%	524	$740.68
86376		<1%	53	$701.63
82977		<1%	101	$691.15
84550		<1%	145	$617.16
86703		<1%	54	$570.48
82627		<1%	29	$549.72
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	18	$480.70
84144		<1%	25	$432.44
87563		<1%	13	$392.65
81241		<1%	201	$355.75
84146		<1%	16	$253.60
81001		<1%	95	$224.10
80349		<1%	32	$207.00
80336		<1%	80	$206.83
87511		<1%	19	$173.24
87086	Culture, bacterial; quantitative colony count, urine	<1%	19	$167.80
86592		<1%	44	$158.70
81025		<1%	21	$137.25
85046		<1%	25	$133.68
84100		<1%	16	$39.99
81230		0%	202	$0.00
81231		0%	200	$0.00
81306		0%	58	$0.00
81401		0%	201	$0.00
81328		0%	201	$0.00
81355		0%	188	$0.00
81479	Unlisted molecular pathology procedure	0%	1,777	$0.00
81335		0%	190	$0.00
G0659	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes	0%	70	$0.00
80360		0%	19	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialAHMED, MAQSOOD (OWNER)

Same official

Other billing entities under AHMED, MAQSOOD

Full network →

Provider	Location	Paid
Family Medicine & Rehabilitation Center, PC	Goldsboro, NC	$2.03M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.